Evidence map›Paper›PMID 40671471›Full record

ArticleNanomedicine (London, England)2025

Phospholipid-based nanolipid carriers for dual kinase inhibitors in triple-negative breast cancer.

Nabil K Alruwaili, Waleed H Almalki, Salem Salman Almujri, Abdulrahman Alhamyani, Abdulaziz Alzahrani, Alhussain Aodah, Majed Alrobaian, Tanuja Singh, Md Abul Barkat, Abdulkareem Ali Alanezi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nabil K AlruwailiDepartment of Pharmaceutics, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia.
Waleed H AlmalkiDepartment of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Salem Salman AlmujriDepartment of Pharmacology, College of Pharmacy, King Khalid University, Asir-Abha, Saudi Arabia.
Abdulrahman AlhamyaniPharmaceuticals Chemistry Department, Faculty of Clinical Pharmacy, Al Baha University, Al Baha, Saudi Arabia.
Abdulaziz AlzahraniPharmaceuticals Chemistry Department, Faculty of Clinical Pharmacy, Al Baha University, Al Baha, Saudi Arabia.
Alhussain AodahCollege of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.ORCID 0000-0002-5344-0777
Majed AlrobaianDepartment of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Tanuja SinghCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Md Abul BarkatDepartment of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, Al Jamiah, Hafr Al Batin, Saudi Arabia.ORCID 0000-0001-6009-5222
Abdulkareem Ali AlaneziDepartment of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, Al Jamiah, Hafr Al Batin, Saudi Arabia.
Anjali SinghDepartment of Research, Principal Scientist, IIR (2nd floor), Vivantes Hospital and Research Institute, Patna, Bihar, India.
Esraa M HajiDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.
Mahfoozur RahmanDepartment of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Allahabad, Uttar Pradesh, India.ORCID 0000-0002-5616-4026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimCurrent research is focused on developing phospholipid-based nanolipidic carrier (NLC) to deliver lapatinib (LNB) and imatinib (INB) to MDA-MB-231 breast cancer cells and an in vivo mammary tumor model. MATERIALS AND

methodsBreast cancer (BC) was induced in female rats via the chemical carcinogen 7, 12-dimethylbenz(a)anthracene (DMBA). The dual drug-loaded phospholipid-based NLC were made via a hot microemulsion process. The developed NLC were also characterized, and tested in vitro, in vivo, and in a preclinical setting in a DMBA-induced rat model.

resultsThe dual drug-loaded phospholipid NLC exhibited favorable nanometric size (279.7 nm, PDI 0.323), high entrapment efficiency (94.21%), and robust loading capacity (13.11%). It achieved biphasic drug release (52.67% at 4 h; 92.12% cumulative), potent cytotoxicity with maximal IC₅₀ reduction at 48 h, and maintained stability under accelerated conditions. In vivo, it significantly reduced tumor burden, normalized hematological and biochemical markers, and demonstrated therapeutic efficacy in DMBA-induced breast cancer, highlighting its translational potential.

conclusionsThe dual drug-loaded NLC not only achieved high entrapment efficiency but also enhanced cytotoxicity against MDA-MB-231 cells and significantly reduced tumor progression. The developed lipid-based nanocarrier system demonstrates strong potential as a targeted platform for the co-delivery of kinase inhibitors, addressing the therapeutic limitations associated with monotherapy and conventional drug formulations.

Indexed as

Antineoplastic AgentsDrug CarriersNanoparticlesPhospholipidsProtein Kinase InhibitorsQuinazolinesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansLapatinibLiposomesPiperazinesRatsRats, Sprague-DawleyAntineoplastic AgentsDrug CarriersLapatinibLiposomesPhospholipidsPiperazinesProtein Kinase InhibitorsQuinazolinesantioxidantsDMBAimatinibinflammatory markersLapatinibmitochondrial enzymesphospholipid-based nanolipid carrierstriple-negative breast cancer

Identifiers

PMID40671471
PMCPMC12320807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.